Business Wire

The Healthcare+ Expo Taiwan Continues to Lead a Medical Innovation Hub With Its Strength in Digital Health, Health Tech and Medicine


Following the success last year, the Healthcare+ Expo sees a rapid growth in size and significance of procurement, networking and marketing. The Expo is now regarded as a primary event in Asia, attracting global participation from more than 5,000 buyers, 500 enterprises, 60 high-profile speakers and 100 professional institutions to come to Taipei on 5-8 December 2019.

This press release features multimedia. View the full release here:

Where key opinion leaders go and business grows

Exhibitors this year have a strong presence in medical AI, health tech and medicine. World-class medical centres, IT giants, international brands for medical devices and innovative startups congregate at the Expo to impress audiences with advanced health tech and life-saving medical development. In addition to that, the Expo sets the theme to digital health utilising AI, IoT, cloud computing and robotics, new technology for cancer treatment, precision health and smart hospitals in response to robust market demands.

As part of the Expo programmes, MEDTEX Summit Asia brings together 10 top venture capital firms, global AI pioneers, a Nobel Prize winner and multinational pharmaceutical executives to project their views on futuristic trends of healthcare. Visitors having business agendas can then anticipate fruitful results gained in conferences, match-making sessions and roadshows, as well as taking home with high quality market insights.

Why Taiwan matters to healthcare industry

Taiwan has a competitive edge as it is situated the heart of Asia, with proximity and commercial links to emerging economics, and a home to leading electronics manufacturers and well-connected supply chains. Coupling with its strength in tech, the healthcare system here provides not only a universal coverage for every citizen but a massive amount of data collected over years that paves the way for Taiwan to excel in wider healthcare business competitions.

The Expo thus invites those who are or will be in healthcare business, to save the date, come prepared and stay connected wherever they are. Visitors with interest in the Expo are suggested booking a place online beforehand (click here); early bird offers are available now until 30 September.

Register now

Expo in detail

Contact information

Research Centre for Biotechnology and Medicine Policy
Gordon Shen PhD. +886 2 2655 7888 Ext.630
Miss Silvia Fan +886 2 2655 7888 Ext.649
David Yang PhD. +886 2 2655 7888 Ext.627

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BrandShield Launches ElectionShield Product to Protect Political Campaigns From Online Threats20.2.2020 10:00:00 EETPress release

BrandShield, a leading provider of services from brand protection to online threat hunting, has today announced the launch of ElectionShield. Developed to protect political campaigns around the World from threats, such as fraudulent fundraising sites; phishing; social phishing; and impersonation, ElectionShield will be officially launched at one the World’s leading cybersecurity events, the RSA Conference in San Francisco, on February 24 - 28, 2020. BrandShield is exhibiting at South Expo, Booth# 3119. ElectionShield utilizes BrandShield’s market-leading technology to protect political campaigns and candidates from a growing range of online threats. These include social impersonation; fraudulent fundraising schemes; domain squatting; sale of unauthorized merchandise; fake social media content; phishing, social phishing and fake news. The last few years have seen a proliferation of fake social media content, in some cases using ‘deep fake’ video, designed to attack politicians. Accordin

Breath Therapeutics, a Zambon company, initiates BOSTON-3 and BOSTON-4, two additional clinical studies for the treatment of bronchiolitis obliterans syndrome (BOS)20.2.2020 09:00:00 EETPress release

Zambon, a multinational pharmaceutical company that focuses on innovation and development with the aim to improve the quality of people’s health and patients’ lives, and Breath Therapeutics, a Zambon company, specializing in advanced inhaled therapeutics for severe respiratory diseases, announced today the initiation of the BOSTON-4 phase 2 multi-center clinical study of Liposomal Cyclosporine A for Inhalation (L‑CsA‑i) for the treatment of bronchiolitis obliterans syndrome (BOS) following allogeneic hematopoietic stem cell transplant (alloHSCT). Additionally, the BOSTON-3 open-label extension study has been initiated and is open to eligible participants who complete the BOSTON‑1 and ‑2 phase 3 studies currently underway to evaluate L‑CsA‑i for the treatment of BOS following lung transplantation. Anne Bergeron, MD, PhD, Prof, Hôpital Saint Louis, Paris said, “Bronchiolitis obliterans syndrome is the primary noninfectious pulmonary complication in patients who undergo allogeneic HSCT. D

ADVA posts annual revenues of EUR 556.8 million for 201920.2.2020 09:00:00 EETPress release

ADVA (ISIN: DE0005103006), a leading provider of open networking solutions for the delivery of cloud and mobile services, reported financial results for Q4 and full year 2019 ended on December 31, 2019. The results have been prepared in accordance with International Financial Reporting Standards (IFRS). This press release features multimedia. View the full release here: Brian Protiva, CEO, ADVA (Photo: Business Wire) Q4 2019 financial summary 1 (in thousands of EUR) Q4 Q4 Change Q3 Change 2019 2018 2019 Revenues 151,135 131,513 14.9% 144,310 4.7% Pro forma gross profit 54,633 48,665 12.3% 49,086 11.3% in % of revenues 36.1% 37.0% -0.9pp 34.0% 2.1pp Pro forma operating income 10,333 8,106 27.5% 7,393 39.8% in % of revenues 6.8% 6.2% 0.6pp 5.1% 1.7pp Operating income 2 5,438 6,332 -14.1% 3,200 69.9% Net income 2 2,522 3,633 -30.6% 2,190 15.2% (in thousands of EUR) Dec. 31 2019 Dec. 31 2018 Change Sep. 30 2019 Change Cash and cash

Lenovo Delivers Record Setting Q3 Performance With All Time Revenue And PTI Highs20.2.2020 07:18:00 EETPress release

Lenovo Group (HKSE: 992) (Pink Sheets: LNVGY) today announced Group revenue in the third quarter reached a record high of US$14.1 billion, and the tenth consecutive year-on-year quarter of growth. Pre-tax income grew 11% compared to the same quarter a year earlier, to US$390 million and net income also increased 11% year-on-year to US$258 million. Basic earnings per share for the third quarter were 2.16 US cents or 16.90 HK cents. “Last quarter, despite the geopolitical uncertainties and industry-wide supply shortages, we delivered a record-setting performance with geographical balance, operational excellence, and solid strategy execution. Both group revenue and pre-tax income reached all-time highs,” said Yang Yuanqing, Lenovo Chairman and CEO. “These core competencies not only enable us to seize the opportunities of technology transformation and drive sustainable growth, but also help us address the challenges we face today.” Global economic factors The last quarter has presented mul

Australian Government and Rimini Street Establish Whole-of-Government Agreement20.2.2020 02:00:00 EETPress release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that it has established a new whole-of-government volume sourcing agreement with the Australian Government, which has the potential to generate significant savings on enterprise software support for government. The agreement is part of the government’s agenda to transform ICT procurement to make it simpler, clearer and faster for agencies and industry to transact services. This press release features multimedia. View the full release here: Australian Government and Rimini Street Establish Whole-of-Government Agreement (Graphic: Business Wire) Chief executive officer of the Australian Government’s Digital Transformation Agency, Mr. Randall Brugeaud, said the agreement with Rimini Street will make it easier and mor

BIOCORP: Marketing Partnership on Mallya with iSage Rx in the Field of Digital Diabetes19.2.2020 20:00:00 EETPress release

Regulatory News: BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / Eligible PEA PME), a French company specialized in the development and manufacturing of medical devices and smart drug delivery systems, today announced an alliance with US-based iSage Rx, LLC., a digital therapeutics company, focused on insulin dose optimization. In detail, the two companies are committed to integrating their respective technologies to simplify insulin dose capture and optimization. The integration of Mallya (a CE-marked connected device dedicated to insulin pens) into the iSage app (a clinically validated insulin titration platform cleared by the FDA) should enable patients with type 2 diabetes to simplify their insulin management. This will allow patients with diabetes to seamlessly capture, record, and store information about their insulin injections and while receiving automated guidance on how to adjust their insulin dose overtime ("titration"). Ryan Sysko, President and CEO of Amalgam Rx, Inc, said:

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom